Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity.

Quagliariello V, Vecchione R, Coppola C, Di Cicco C, De Capua A, Piscopo G, Paciello R, Narciso V, Formisano C, Taglialatela-Scafati O, Iaffaioli RV, Botti G, Netti PA, Maurea N.

Nutrients. 2018 Sep 14;10(9). pii: E1304. doi: 10.3390/nu10091304.

2.

Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine.

De Lorenzo C, Paciello R, Riccio G, Rea D, Barbieri A, Coppola C, Maurea N.

Onco Targets Ther. 2018 Apr 19;11:2241-2250. doi: 10.2147/OTT.S157294. eCollection 2018.

3.

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production.

Riccio G, Antonucci S, Coppola C, D'Avino C, Piscopo G, Fiore D, Maurea C, Russo M, Rea D, Arra C, Condorelli G, Di Lisa F, Tocchetti CG, De Lorenzo C, Maurea N.

Front Physiol. 2018 Feb 6;9:38. doi: 10.3389/fphys.2018.00038. eCollection 2018.

4.

Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.

Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N.

Cancer Treat Rev. 2018 Feb;63:135-143. doi: 10.1016/j.ctrv.2017.11.009. Epub 2017 Dec 6. Review.

5.

Essure Permanent Birth Control, Effectiveness and Safety: An Italian 11-Year Survey.

Franchini M, Zizolfi B, Coppola C, Bergamini V, Bonin C, Borsellino G, Busato E, Calabrese S, Calzolari S, Fantin GP, Giarrè G, Litta P, Luerti M, Mangino FP, Marchino GL, Molinari MA, Scatena E, Scrimin F, Telloli P, Di Spiezio Sardo A.

J Minim Invasive Gynecol. 2017 May - Jun;24(4):640-645. doi: 10.1016/j.jmig.2017.02.004. Epub 2017 Feb 14.

PMID:
28232037
6.

Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking.

Coppola C, Riccio G, Barbieri A, Monti MG, Piscopo G, Rea D, Arra C, Maurea C, De Lorenzo C, Maurea N.

Onco Targets Ther. 2016 Nov 2;9:6785-6794. eCollection 2016.

7.

Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.

Bassareo PP, Monte I, Romano C, Deidda M, Piras A, Cugusi L, Coppola C, Galletta F, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e55-e63. Review.

PMID:
27755243
8.

Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.

Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa P, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e19-e26. Review.

PMID:
27755239
9.

Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.

Bassareo PP, Monte I, Romano C, Deidda M, Piras A, Cugusi L, Coppola C, Galletta F, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S55-63. doi: 10.2459/JCM.0000000000000375. Review.

PMID:
27183526
10.

Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.

Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa P, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S19-26. doi: 10.2459/JCM.0000000000000377. Review.

PMID:
27183521
11.

Strain Analysis in the Assessment of a Mouse Model of Cardiotoxicity due to Chemotherapy: Sample for Preclinical Research.

Rea D, Coppola C, Barbieri A, Monti MG, Misso G, Palma G, Bimonte S, Zarone MR, Luciano A, Liccardo D, Maiolino P, Cittadini A, Ciliberto G, Arra C, Maurea N.

In Vivo. 2016 May-Jun;30(3):279-90.

PMID:
27107087
12.

WITHDRAWN:A Practical Approach for Management of QT Prolongation Induced by Anticancer Drugs.

Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, De Lorenzo C.

Oncologist. 2016 Mar 14. pii: theoncologist.2015-0313. [Epub ahead of print] Review.

13.

Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?

Riccio G, Coppola C, Piscopo G, Capasso I, Maurea C, Esposito E, De Lorenzo C, Maurea N.

Hum Vaccin Immunother. 2016 May 3;12(5):1124-31. doi: 10.1080/21645515.2015.1125056. Epub 2016 Feb 2.

14.

Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype.

Capasso I, Esposito E, de Laurentiis M, Maurea N, Cavalcanti E, Botti G, Petrillo A, Montella M, D'Aiuto M, Coppola C, Crispo A, Grimaldi M, Frasci G, Fucito A, Ciliberto G, D'Aiuto G.

Diabetol Metab Syndr. 2014 Sep 26;6(1):105. doi: 10.1186/1758-5996-6-105. eCollection 2014.

15.

Ultrasound assessment of the Essure contraceptive devices: is three-dimensional ultrasound really needed?

Paladini D, Di Spiezio Sardo A, Coppola C, Zizolfi B, Pastore G, Nappi C.

J Minim Invasive Gynecol. 2015 Jan;22(1):115-21. doi: 10.1016/j.jmig.2014.08.010. Epub 2014 Aug 23.

PMID:
25241073
16.

Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.

Tocchetti CG, Carpi A, Coppola C, Quintavalle C, Rea D, Campesan M, Arcari A, Piscopo G, Cipresso C, Monti MG, De Lorenzo C, Arra C, Condorelli G, Di Lisa F, Maurea N.

Eur J Heart Fail. 2014 Apr;16(4):358-66.

17.

Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.

D'Avino C, Paciello R, Riccio G, Coppola C, Laccetti P, Maurea N, Raines RT, De Lorenzo C.

Protein Eng Des Sel. 2014 Mar;27(3):83-8. doi: 10.1093/protein/gzt065. Epub 2014 Jan 12. Erratum in: Protein Eng Des Sel. 2014 May;27(5):177. Coppola, Melina [corrected to Coppola, Carmela].

18.

The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors.

Tocchetti CG, Gallucci G, Coppola C, Piscopo G, Cipresso C, Maurea C, Giudice A, Iaffaioli RV, Arra C, Maurea N.

Eur J Heart Fail. 2013 May;15(5):482-9. doi: 10.1093/eurjhf/hft008. Epub 2013 Jan 16. Review.

19.

Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge.

Tocchetti CG, Ragone G, Coppola C, Rea D, Piscopo G, Scala S, De Lorenzo C, Iaffaioli RV, Arra C, Maurea N.

Eur J Heart Fail. 2012 Feb;14(2):130-7. doi: 10.1093/eurjhf/hfr165. Epub 2012 Jan 4. Review.

20.

Early identification of left ventricular dysfunction induced by trastuzumab.

Tocchetti CG, Coppola C, Arra C, Maurea N.

J Am Coll Cardiol. 2011 Dec 13;58(25):2698-9; author reply 2699-700. doi: 10.1016/j.jacc.2011.08.056. No abstract available.

Supplemental Content

Loading ...
Support Center